RNXT's logo.
Ticker Symbol: RNXT

RenovoRx Inc

$7.02 - 07-11-2024 4 p.m. ET

Exchange: NASDAQ Currency: USD Asset Type: Common Stock CIK:0001574094

Company Profile

RenovoRx, a biopharmaceutical company headquartered in Silicon Valley, California, has developed a therapy platform targeting difficult-to-treat tumors. Targeted therapy via the proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) platform safely and without transmission to non-targeted areas, is the primary focus. RenovoRx's patent portfolio includes seven U.S. patents for its technology. The Company also has secured two separate Orphan Drug Designations from the FDA for intra-arterial gemcitabine including pancreatic cancer and bile duct cancer. The RenovoTAMP therapy is being studied in the Phase III TIGeR-PaC trial for the treatment of locally advanced pancreatic cancer. RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its RenovoTAMP technology.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
CEO: N/A
Tags: N/A

Pricing

Last Updated: October 13, 2023 03:30 PM EST
Previous Close: $1.11
Change: -$0.11 ( -9.02%)
Days Range: $1.08 - $1.20
Beta: 1.00
52wk. High: $5.75
52wk. Low: $0.91
Ytd. Change -61.78%
50 Day Moving Average: $1.32
200 Day Moving Average: $1.99
Shares Outstanding: 10693080

Valuation

Market Cap: 1.2B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A